论文部分内容阅读
VP-16(鬼臼毒素的衍生物)是对以前不能治疗的小细胞肺癌最有效的一种药物,可单独应用。在二期临床试验中,已报告其有效率为20～60％。顺铂对小细胞肺癌效果较差,然而VP-16与顺铂合用已表现出对某些动物肿瘤有协同作用。对CAV(环磷酰胺、阿霉素及长春新碱)化疗无效的,单独用VP-16也无效,然而VP-16与顺铂合用对55％的病人有效果。另外,VP-16与顺铂合用对以前未接受过治疗的病人极为有效。加拿大多伦多总医院和安大略癌症研究所的研究人员,对心、肝功能不好不能接受CAV
VP-16 (derivative of podophyllotoxin) is the most effective drug for small cell lung cancer that could not be treated before and can be used alone. In phase II clinical trials, effective rates of 20 to 60% have been reported. Cisplatin is less effective against small cell lung cancer, however, the combination of VP-16 and cisplatin has shown synergistic effects on certain animal tumors. Ineffective for CAV (cyclophosphamide, doxorubicin, and vincristine) chemotherapy alone, VP-16 alone was also ineffective, whereas VP-16 combined with cisplatin was effective in 55% of patients. In addition, the combination of VP-16 and cisplatin is extremely effective for patients who have not previously received treatment. Researchers at the Toronto General Hospital and the Ontario Cancer Institute have poor heart and liver function and cannot accept CAV